At the 61st ASH Annual Meeting & Exposition, Editor-in-Chief of Oncology & Hematology Review (US) Shaji Kumar (Mayo Clinic) discusses the latest advances in the treatment and guidelines of multiple myeloma.
1. What have been the most exciting recent development in the treatment of multiple myeloma? (0:05)
2. According to the most recent guidelines, what criteria are used to assess eligibility for autologous stem-cell transplant (ASCT)? (1:52)
3. What are the options for first-line therapy in transplant-ineligible patients? (3:38)
4. What factors influence the choice of first relapse therapy? (5:30)
5. How does risk status influence therapy in myeloma (newly diagnosed and relapse)? (6:36)
Shaji Kumar has no conflicts of interest to declare in relation to this video.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
Share this Video
Related Videos In Multiple Myeloma
Shaji Kumar, ASCO 2021: The EQUATE Trial, a Quadruplet Regimen for Multiple Myeloma
We were delighted to talk with Dr Shaji Kumar (Mayo Clinic, Rochester, MN, USA) about the EQUATE trial, developing a quadruplet regimen for newly-diagnosed multiple myeloma, including bortezomib, lenalidomide, dexamethasone and daratumumab. The abstract ‘ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended […]
Shaji Kumar, ASH 2020 – Highlights from ASH 2020
It was a pleasure to speak with our Editor-in-Chief, Shaji Kumar (Mayo Clinic, Rochester, MN, USA) to discuss the use of MEDI2228 (Clinical Trial Identifier: NCT03489525) and anti-BCMA CAR-T cells (Clinical Trial Identifier: NCT03915184) in the treatment of patients with relapsed/refractory multiple myeloma and to find out his personal highlights from this year’s congress. The […]
Meletios-Athanasios Dimopoulos, ASH 2020 – Results from the Apollo Trial
We caught up with Meletios-Athanasios Dimopoulos (National and Kapodistrian University of Athens School of Medicine, Athens, Greece) to discuss his ASH 2020 presentation on the use of daratumumab in the treatment of relapsed/refractory multiple myeloma (Clinical Trial Identification: NCT03180736). The abstract ‘412 Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!